Multiple Myeloma Research Consortium
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
Clinical Trials
4
Active:0
Completed:1
Trial Phases
3 Phases
Phase 1:2
Phase 2:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Not Applicable
1 (25.0%)Phase 2
1 (25.0%)Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma
Not Applicable
Not yet recruiting
- Conditions
- High Risk Newly Diagnosed Multiple Myeloma
- Interventions
- Drug: Monoclonal Antibody with Stem Cell TransplantDrug: Bispecific Monoclonal Antibody and Triplet Therapy
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Multiple Myeloma Research Consortium
- Target Recruit Count
- 300
- Registration Number
- NCT07053436
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
Phase 2
Recruiting
- Conditions
- Refractory Multiple MyelomaRelapse Multiple Myeloma
- Interventions
- Drug: Teclistamab Monotherapy
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Multiple Myeloma Research Consortium
- Target Recruit Count
- 300
- Registration Number
- NCT06171685
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Emory Winship Cancer Center, Atlanta, Georgia, United States
🇺🇸University of Chicago Cancer Center, Chicago, Illinois, United States
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Phase 1
Terminated
- Conditions
- Relapsed Refractory Multiple MyelomaMultiple Myeloma
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Multiple Myeloma Research Consortium
- Target Recruit Count
- 14
- Registration Number
- NCT04150965
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Myeloma-Developing Regimens Using Genomics (MyDRUG)
Phase 1
Completed
- Conditions
- Relapsed Refractory Multiple Myeloma
- Interventions
- Drug: Abemaciclib, dexamethasone, ixazomib, pomalidomideDrug: Enasidenib, dexamethasone, ixazomib, pomalidomideDrug: Cobimetinib, dexamethasone, ixazomib, pomalidomideDrug: Erdafitinib, dexamethasone, ixazomib, pomalidomideDrug: Venetoclax, dexamethasone, ixazomib, pomalidomideDrug: Daratumumab, dexamethasone, ixazomib, pomalidomideDrug: Belantamab mafodotin, dexamethasone, ixazomib, pomalidomideDrug: Selinexor, dexamethasone, ixazomib, pomalidomide
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Multiple Myeloma Research Consortium
- Target Recruit Count
- 103
- Registration Number
- NCT03732703
- Locations
- 🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
News
No news found